NeoGenomics (MEX:NEO) Notes Receivable: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
74 GF Score
Price MXN176.40
GF Value MXN177.40
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Notes Receivable?

NeoGenomics MEX:NEO 74 Notes Receivable is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 74/100 and a GF Value™ of MXN177.40. The stock has 6 warning signs investors should review.

NeoGenomics's Notes Receivable for the quarter that ended in Jun. 2026 was MXN0 Mil.

NeoGenomics Notes Receivable Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Notes Receivable Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:NEO
74GF Score
NeoGenomics Inc MEX:NEO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of MXN0 Mil mean?
NeoGenomics (MEX:NEO) has a Notes Receivable of MXN0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Notes Receivable too high?
NeoGenomics' current Notes Receivable is MXN0 Mil. Overall, NeoGenomics has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Notes Receivable compare to WGS and CDNA?
NeoGenomics' Notes Receivable of MXN0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on NeoGenomics and its competitors. NeoGenomics's current Notes Receivable is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Notes Receivable of MXN0 Mil. The stock's GF Value™ is MXN177.40, compared to a current price of MXN176.40 — trading 0.6% below its estimated fair value. The current Notes Receivable is MXN0 Mil. NeoGenomics' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Notes Receivable is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 0.6% below its estimated GF Value™ of MXN177.40.

Key valuation signals for MEX:NEO:

  • Notes Receivable: MXN0 Mil
  • GF Value™: MXN177.40 vs. price of MXN176.40 (0.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
74GF Score

Get the complete analysis for MEX:NEO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN177.40
GF Value